# GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement - Company: GILEAD SCIENCES, INC. (GILD) - Period: 2024-01-01 to 2024-09-30 - Filing: Q3 FY2024 10-Q, filed 2024-11-12, accession number 0000882095-24-000028 - Page: https://plicit.ai/financials/gild/fy2024-ytd-q3-income-statement - Chart image: https://plicit.ai/charts/gild-fy2024-ytd-q3-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 21,185,000,000 US dollars - **Cost of goods sold**: 4,670,000,000 US dollars - **Gross profit (calculated)**: 16,515,000,000 US dollars - **Operating expenses (calculated)**: 17,305,000,000 US dollars - **Operating income (loss)**: negative 790,000,000 US dollars - **Other income (expense), net (calculated)**: negative 687,000,000 US dollars - **Income (loss) before income taxes**: negative 1,477,000,000 US dollars - **Income tax (benefit) expense**: negative 174,000,000 US dollars - **Net income (loss)**: negative 1,303,000,000 US dollars - **Tecartus - UNITED STATES**: 181,000,000 US dollars - **Tecartus - Rest of World**: 22,000,000 US dollars - **Tecartus - Europe**: 102,000,000 US dollars - **Total Cell Therapy - UNITED STATES**: 683,000,000 US dollars - **Total Cell Therapy - Rest of World**: 192,000,000 US dollars - **Total Cell Therapy - Europe**: 611,000,000 US dollars - **Yescarta - UNITED STATES**: 502,000,000 US dollars - **Yescarta - Rest of World**: 170,000,000 US dollars - **Yescarta - Europe**: 509,000,000 US dollars - **Total HIV - UNITED STATES**: 11,386,000,000 US dollars - **Total HIV - Rest of World**: 1,038,000,000 US dollars - **Total HIV - Europe**: 1,737,000,000 US dollars - **Biktarvy - UNITED STATES**: 7,726,000,000 US dollars - **Biktarvy - Rest of World**: 814,000,000 US dollars - **Biktarvy - Europe**: 1,110,000,000 US dollars - **Descovy - UNITED STATES**: 1,339,000,000 US dollars - **Descovy - Rest of World**: 82,000,000 US dollars - **Descovy - Europe**: 75,000,000 US dollars - **Genvoya - UNITED STATES**: 1,088,000,000 US dollars - **Genvoya - Rest of World**: 66,000,000 US dollars - **Genvoya - Europe**: 138,000,000 US dollars - **Odefsey - UNITED STATES**: 705,000,000 US dollars - **Odefsey - Rest of World**: 30,000,000 US dollars - **Odefsey - Europe**: 217,000,000 US dollars - **Other HIV - UNITED STATES**: 190,000,000 US dollars - **Other HIV - Rest of World**: 36,000,000 US dollars - **Other HIV - Europe**: 96,000,000 US dollars - **Symtuza - Revenue share - UNITED STATES**: 338,000,000 US dollars - **Symtuza - Revenue share - Rest of World**: 9,000,000 US dollars - **Symtuza - Revenue share - Europe**: 101,000,000 US dollars - **Total Liver Disease - UNITED STATES**: 1,210,000,000 US dollars - **Total Liver Disease - Rest of World**: 682,000,000 US dollars - **Total Liver Disease - Europe**: 411,000,000 US dollars - **Other Liver Disease - UNITED STATES**: 134,000,000 US dollars - **Other Liver Disease - Rest of World**: 55,000,000 US dollars - **Other Liver Disease - Europe**: 148,000,000 US dollars - **Sofosbuvir/Velpatasvir - UNITED STATES**: 737,000,000 US dollars - **Sofosbuvir/Velpatasvir - Rest of World**: 299,000,000 US dollars - **Sofosbuvir/Velpatasvir - Europe**: 230,000,000 US dollars - **Vemlidy - UNITED STATES**: 338,000,000 US dollars - **Vemlidy - Rest of World**: 328,000,000 US dollars - **Vemlidy - Europe**: 33,000,000 US dollars - **Total Oncology - UNITED STATES**: 1,338,000,000 US dollars - **Total Oncology - Rest of World**: 280,000,000 US dollars - **Total Oncology - Europe**: 828,000,000 US dollars - **AmBisome - UNITED STATES**: 37,000,000 US dollars - **AmBisome - Rest of World**: 176,000,000 US dollars - **AmBisome - Europe**: 210,000,000 US dollars - **Other - UNITED STATES**: 203,000,000 US dollars - **Other - Rest of World**: 52,000,000 US dollars - **Other - Europe**: 26,000,000 US dollars - **Total Other - UNITED STATES**: 241,000,000 US dollars - **Total Other - Rest of World**: 228,000,000 US dollars - **Total Other - Europe**: 236,000,000 US dollars - **Royalty, contract and other revenues - UNITED STATES**: 66,000,000 US dollars - **Royalty, contract and other revenues - Rest of World**: 2,000,000 US dollars - **Royalty, contract and other revenues - Europe**: 43,000,000 US dollars - **Trodelvy - UNITED STATES**: 655,000,000 US dollars - **Trodelvy - Rest of World**: 88,000,000 US dollars - **Trodelvy - Europe**: 217,000,000 US dollars - **Veklury - UNITED STATES**: 784,000,000 US dollars - **Veklury - Rest of World**: 473,000,000 US dollars - **Veklury - Europe**: 204,000,000 US dollars - **Product sales - UNITED STATES**: 14,958,000,000 US dollars - **Product sales - Rest of World**: 2,700,000,000 US dollars - **Product sales - Europe**: 3,416,000,000 US dollars - **Selling, general and administrative expenses**: 4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **In-process research and development impairment**: 4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 63,359,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 42,174,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (16 categories) - Page: https://plicit.ai/financials/gild/fy2024-ytd-q3-income-statement/revenue-by-product-and-service-16-categories - Chart image: https://plicit.ai/charts/gild-fy2024-ytd-q3-revenue-by-product-and-service-16-categories-sankey.png Income statement for 2024-01-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 21,185,000,000 US dollars - **Cost of goods sold**: 4,670,000,000 US dollars - **Gross profit (calculated)**: 16,515,000,000 US dollars - **Operating expenses (calculated)**: 17,305,000,000 US dollars - **Operating income (loss)**: negative 790,000,000 US dollars - **Other income (expense), net (calculated)**: negative 687,000,000 US dollars - **Income (loss) before income taxes**: negative 1,477,000,000 US dollars - **Income tax (benefit) expense**: negative 174,000,000 US dollars - **Net income (loss)**: negative 1,303,000,000 US dollars - **Tecartus**: 305,000,000 US dollars - **Yescarta**: 1,181,000,000 US dollars - **Biktarvy**: 9,649,000,000 US dollars - **Descovy**: 1,496,000,000 US dollars - **Genvoya**: 1,292,000,000 US dollars - **Odefsey**: 952,000,000 US dollars - **Symtuza - Revenue share**: 448,000,000 US dollars - **Other HIV**: 322,000,000 US dollars - **Sofosbuvir/Velpatasvir**: 1,266,000,000 US dollars - **Vemlidy**: 699,000,000 US dollars - **Other Liver Disease**: 337,000,000 US dollars - **Trodelvy**: 960,000,000 US dollars - **AmBisome**: 424,000,000 US dollars - **Other**: 281,000,000 US dollars - **Royalty, contract and other revenues**: 111,000,000 US dollars - **Veklury**: 1,461,000,000 US dollars - **Undisclosed (calculated)**: 1,000,000 US dollars - **Selling, general and administrative expenses**: 4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **In-process research and development impairment**: 4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/gild/fy2024-ytd-q3-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/gild-fy2024-ytd-q3-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2024-01-01 through 2024-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 21,185,000,000 US dollars - **Cost of goods sold**: 4,670,000,000 US dollars - **Gross profit (calculated)**: 16,515,000,000 US dollars - **Operating expenses (calculated)**: 17,305,000,000 US dollars - **Operating income (loss)**: negative 790,000,000 US dollars - **Other income (expense), net (calculated)**: negative 687,000,000 US dollars - **Income (loss) before income taxes**: negative 1,477,000,000 US dollars - **Income tax (benefit) expense**: negative 174,000,000 US dollars - **Net income (loss)**: negative 1,303,000,000 US dollars - **Product sales**: 21,074,000,000 US dollars - **Royalty, contract and other revenues**: 111,000,000 US dollars - **Selling, general and administrative expenses**: 4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **In-process research and development impairment**: 4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/gild/fy2024-ytd-q3-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/gild-fy2024-ytd-q3-revenue-by-geography-sankey.png Income statement for 2024-01-01 through 2024-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 21,185,000,000 US dollars - **Cost of goods sold**: 4,670,000,000 US dollars - **Gross profit (calculated)**: 16,515,000,000 US dollars - **Operating expenses (calculated)**: 17,305,000,000 US dollars - **Operating income (loss)**: negative 790,000,000 US dollars - **Other income (expense), net (calculated)**: negative 687,000,000 US dollars - **Income (loss) before income taxes**: negative 1,477,000,000 US dollars - **Income tax (benefit) expense**: negative 174,000,000 US dollars - **Net income (loss)**: negative 1,303,000,000 US dollars - **UNITED STATES**: 15,024,000,000 US dollars - **Europe**: 3,459,000,000 US dollars - **Rest of World**: 2,703,000,000 US dollars - **Selling, general and administrative expenses**: 4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **In-process research and development impairment**: 4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 21,186,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.